---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-24-000057"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:38:17.156342+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B

## Summary
- GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.
- Net product sales $1.8B (+4% YoY); COVID-19 sales $1.8B, RSV sales $10M (below expectations).
- FY 2024 product sales guidance reiterated at $3.0-3.5B; cost of sales guidance narrowed to 40-45%.
- R&D lowered to $4.6-4.7B; capex raised to ~$1.2B including Norwood campus purchase ($0.4B).
- Initiated Phase 3 trials for norovirus and influenza vaccines; expanded Executive Committee.

## SEC filing metadata
- accession: 0001682852-24-000057
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000057/0001682852-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285224000057/mrna-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-24-000057
- JSON: https://secwatch.observer/filing/0001682852-24-000057.json
- Plain text: https://secwatch.observer/filing/0001682852-24-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.